THE LANCET JOURNALS: Papers publishing during the European Society for Medical Oncology Congress 2023 (#ESMO 2023), 20th – 24th October 2023
The following Lancet papers will be presented at the European Society for Medical Oncology Congress 2023 (#ESMO 2023). The conference will take place between Friday 20th – Tuesday 24th October 2023.
Contact details for corresponding authors are provided should you wish to arrange an interview with the authors. Funding information is listed on the first page of each Article.
**Embargo: 13.00 [BST] / 14.00 [CEST] Friday 20th October 2023**
The Lancet: Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Article available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO1.pdf
Linked comment available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO1LC.pdf
Appendix available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO1APPX.pdf
Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lancet/article/PIiS0140-6736(23)02033-0/fulltext
For interviews with the authors, please contact: Yelena Janjigian, E) janjigiy@mskcc.org
**Embargo: 08.00 [BST] / 09.00 [CEST] Saturday 21st October 2023**
The Lancet Oncology: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Article available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO2.pdf
Linked comment available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO2LC.pdf
Appendix available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO2APPX.pdf
Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00515-6/fulltext
For interviews with the authors, please contact: Sun Young Rha, E) rha7655@yuhs.ac
**Embargo: 13.45 [BST] / 14.45 [CEST] Saturday 21st October 2023**
The Lancet Oncology: Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
Article available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO3.pdf
Appendix available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO3APPX.pdf
Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00459-X/fulltext
For interviews with the authors, please contact: Neil D Gross, E) ngross@mdanderson.org / +1 832 829-0761
END
Contact details for corresponding authors are provided should you wish to arrange an interview with the authors. Funding information is listed on the first page of each Article.
**Embargo: 13.00 [BST] / 14.00 [CEST] Friday 20th October 2023**
The Lancet: Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Article available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO1.pdf
Linked comment available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO1LC.pdf
Appendix available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO1APPX.pdf
Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lancet/article/PIiS0140-6736(23)02033-0/fulltext
For interviews with the authors, please contact: Yelena Janjigian, E) janjigiy@mskcc.org
**Embargo: 08.00 [BST] / 09.00 [CEST] Saturday 21st October 2023**
The Lancet Oncology: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Article available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO2.pdf
Linked comment available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO2LC.pdf
Appendix available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO2APPX.pdf
Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00515-6/fulltext
For interviews with the authors, please contact: Sun Young Rha, E) rha7655@yuhs.ac
**Embargo: 13.45 [BST] / 14.45 [CEST] Saturday 21st October 2023**
The Lancet Oncology: Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
Article available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO3.pdf
Appendix available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/ESMO3APPX.pdf
Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00459-X/fulltext
For interviews with the authors, please contact: Neil D Gross, E) ngross@mdanderson.org / +1 832 829-0761
END